CN103130895A - 抗突触泡蛋白的特异结合成员 - Google Patents

抗突触泡蛋白的特异结合成员 Download PDF

Info

Publication number
CN103130895A
CN103130895A CN2013100289746A CN201310028974A CN103130895A CN 103130895 A CN103130895 A CN 103130895A CN 2013100289746 A CN2013100289746 A CN 2013100289746A CN 201310028974 A CN201310028974 A CN 201310028974A CN 103130895 A CN103130895 A CN 103130895A
Authority
CN
China
Prior art keywords
specific binding
binding member
seq
region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013100289746A
Other languages
English (en)
Chinese (zh)
Inventor
马修.赖特
安迪.波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0407059A external-priority patent/GB0407059D0/en
Priority claimed from GB0416402A external-priority patent/GB0416402D0/en
Application filed by University of Aberdeen filed Critical University of Aberdeen
Publication of CN103130895A publication Critical patent/CN103130895A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2013100289746A 2004-03-29 2005-03-29 抗突触泡蛋白的特异结合成员 Pending CN103130895A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0407059.5 2004-03-29
GB0407059A GB0407059D0 (en) 2004-03-29 2004-03-29 Specific binding members against synaptophysin
GB0416402.6 2004-07-22
GB0416402A GB0416402D0 (en) 2004-07-22 2004-07-22 Specific binding members against synaptophysin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200580017473 Division CN1980958A (zh) 2004-03-29 2005-03-29 抗突触泡蛋白的特异结合成员

Publications (1)

Publication Number Publication Date
CN103130895A true CN103130895A (zh) 2013-06-05

Family

ID=35064446

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013100289746A Pending CN103130895A (zh) 2004-03-29 2005-03-29 抗突触泡蛋白的特异结合成员

Country Status (8)

Country Link
US (2) US7871782B2 (https=)
EP (1) EP1735347B1 (https=)
JP (2) JP5020808B2 (https=)
KR (1) KR101205655B1 (https=)
CN (1) CN103130895A (https=)
CA (1) CA2584608C (https=)
PL (1) PL1735347T3 (https=)
WO (1) WO2005095453A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1735347T3 (pl) * 2004-03-29 2013-04-30 The Univ Court Of The Univ Of Aberdeen Specyficznie wiążące cząsteczki przeciwko synaptofizynie
CN105968209B (zh) 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
KR102006997B1 (ko) * 2012-07-03 2019-08-02 한국생명공학연구원 ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자
RU2689674C2 (ru) * 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
EP4516316A4 (en) * 2022-04-25 2026-04-22 Jiksak Bioengineering Inc TARGETING AGENT
WO2024055010A1 (en) * 2022-09-08 2024-03-14 Board Of Regents, The University Of Texas System Compositions for treating cancer and methods of using the same
WO2025089349A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプトフィジン抗体
WO2025089347A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプトフィジン抗体
WO2025089348A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプトフィジン抗体
WO2025089343A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプス小胞糖タンパク質２ｃ抗体
WO2025089346A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプトフィジン抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496705A (en) * 1991-08-16 1996-03-05 Kabushiki Kaisha Toshiba Monoclonal antibody specific for rat synaptophysin
WO1999020749A1 (en) * 1997-10-20 1999-04-29 Medical Research Council Method to screen phage display libraries with different ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3940209A1 (de) * 1989-12-05 1991-06-06 Boehringer Mannheim Gmbh Verfahren zum nachweis eines kleinzelligen bronchial-karzinoms
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU6424300A (en) 1999-05-27 2000-12-18 Max-Delbruck-Centrum Fur Molekulare Medizin Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
JP2006510586A (ja) * 2002-08-29 2006-03-30 ユニバーシティー オブ サザンプトン 肝疾患治療のための薬剤の調製におけるアポトーシス誘導物質の使用方法
PL1735347T3 (pl) * 2004-03-29 2013-04-30 The Univ Court Of The Univ Of Aberdeen Specyficznie wiążące cząsteczki przeciwko synaptofizynie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496705A (en) * 1991-08-16 1996-03-05 Kabushiki Kaisha Toshiba Monoclonal antibody specific for rat synaptophysin
WO1999020749A1 (en) * 1997-10-20 1999-04-29 Medical Research Council Method to screen phage display libraries with different ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID CASSIMAN，ET AL.: "Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers", 《JOURNAL OF HEPATOLOGY》 *

Also Published As

Publication number Publication date
KR20060135046A (ko) 2006-12-28
EP1735347B1 (en) 2012-11-07
JP2008506358A (ja) 2008-03-06
JP5020808B2 (ja) 2012-09-05
WO2005095453A2 (en) 2005-10-13
EP1735347A2 (en) 2006-12-27
US20110165078A1 (en) 2011-07-07
US20080274123A1 (en) 2008-11-06
CA2584608C (en) 2015-03-17
WO2005095453A3 (en) 2006-04-06
WO2005095453B1 (en) 2006-12-21
KR101205655B1 (ko) 2012-12-13
US7871782B2 (en) 2011-01-18
JP2012162551A (ja) 2012-08-30
PL1735347T3 (pl) 2013-04-30
CA2584608A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
US20110165078A1 (en) Specific binding members against synaptophysin
CN101687923B (zh) 与肿瘤转移的新生血管有关的纤连蛋白的ed-a抗原
TWI628190B (zh) 可結合及中和ｂ型流感病毒之人類結合分子及其用途
KR101608544B1 (ko) 류마티스 관절염과 연관된 항원
CN101090913B (zh) 抗生腱蛋白c的抗体
CN103212072B (zh) 一种与肺癌和淋巴瘤相关的抗原
EP2314620A1 (en) Binding molecules capable of neutralizing rabies virus and uses thereof
CA3077518C (en) Synthetic antibodies against vegf and their uses
JP2009542202A (ja) デスレセプター５（ｄｒ５）に特異的に結合する抗体及びこれを含む癌の予防又は治療用の組成物
US20240417446A1 (en) Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
US20070104715A1 (en) Antibodies binding to a c-terminal fragment of apoliopoprotein e
JP2006506450A (ja) 粥状動脈硬化の治療用のペプチドベースの受動免疫療法
JP2006506450A5 (https=)
JP6795603B2 (ja) ＥＧＦＲｖＩＩＩ（Ｅｐｉｄｅｒｍａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ Ｒｅｃｅｐｔｏｒ Ｖａｒｉａｎｔ ＩＩＩ）に対する抗体およびその用途
US20240199725A1 (en) Human antibody targeting covid-19 virus
US20230391852A1 (en) Single domain antibodies targeting sars coronavirus spike protein and uses thereof
US8835608B2 (en) Anti-MRP3 antibodies and methods of use
CN1980958A (zh) 抗突触泡蛋白的特异结合成员
HK1185816B (en) An antigen associated with lung cancers and lymphomas
HK1191353B (en) An antigen associated with rheumatoid arthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130605